TMX Newsfile Biotechnology News Releases

Therma Bright Announces up to $420,000 Non-Brokered Private Placement

Fri, 23 Oct 2026 20:37:00 -0400

Toronto, Ontario--(Newsfile Corp. - October 23, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced medical device technologies, announces that it proposes to undertake a non-brokered private placement of up to 14,000,000 common shares (the "Shares") at a price of $0.03/Share for total proceeds of up to $420,000 (the "Offering"). In accordance with the policies of the TSX Venture Exchange...

Defence Therapeutics Announces Convertible Debenture Interest Payment

Fri, 23 Oct 2026 16:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - October 23, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® drug-delivery platform, is pleased to announce convertible debentures interest payment in common shares of the Company. The Company announces that, in accordance with the terms and conditions of convertible debentures...

Global Hemp Group Appoints Mickey Goldstein as Chief Financial Officer, Appoints Davidson & Company as Auditor

Fri, 23 Oct 2026 09:59:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - October 23, 2026) - Global Hemp Group Inc. (CSE: GHG) (FSE: GHG0) (OTC PINK: GBHPF) ("GHG" or the "Company") is pleased to announce the appointment of Mickey Goldstein, CPA, CA, as Chief Financial Officer, effective immediately. Ms. Goldstein succeeds Christopher Cherry.Ms. Goldstein is Director, Accounting Advisory at Crowe MacKay LLP, where she provides strategic financial and advisory services to private and public companies across North America....

PreveCeutical Closes Initial Tranche of Non-Brokered Private Placement

Thu, 22 Oct 2026 17:24:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - October 22, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased announce that, further to its news release dated September 28, 2026, it has closed an initial tranche (the "Initial Tranche") of its previously announced $600,000 non-brokered private placement (the "Offering"), which Initial Tranche consisted of the issuance of 5,200,000 units (each, a "Unit") of the Company at a...

Envoy Medical Announces Reverse Stock Split

Thu, 22 Oct 2026 08:30:00 -0400

White Bear Lake, Minnesota--(Newsfile Corp. - October 22, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announced that it will implement a 1-for-10 reverse stock split of its outstanding shares of Class A common stock ("Common Stock"), effective at 12:01 a.m. Eastern Time on October 26, 2026 (the "Reverse Split"). The Company's Common Stock will continue to trade on...

Envoy Medical Hits Six-Month Milestone, Marks Halfway Point in Final Stage of Data Collection, and Highlights Differentiated Device Design

Tue, 20 Oct 2026 08:30:00 -0400

Company Believes It Is the First to Reach This Milestone in a U.S. Pivotal Trial of a Fully Implanted Cochlear ImplantRemains on Track to Reach 12-Month Visit Milestone by Early Q2 2027 and Submit Final Clinical PMA Module by End of Q2 2027White Bear Lake, Minnesota--(Newsfile Corp. - October 20, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announced that it has...

TempraMed Announces LIFE Offering up to C$8 Million to Accelerate Global Expansion and Fulfilment of Forecasted Demand

Tue, 20 Oct 2026 07:00:00 -0400

Recent Highlights: Record sales: July 2026 sales were about US$522K1, the best month in the company's history, and August was about US$403K, its second-best. Run rate revenue of ~US$5.5M Sales for the first eight months of 2026 were about US$2.07M, already above the US$1.8M booked for all of 2025.Growing patent portfolio: 4 new global patents granted in 2026, for a total ofGlobal distribution: 15 new and renewed distribution commercial relationships signed in 2026, including direct B2B...

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Mon, 19 Oct 2026 09:53:00 -0400

King of Prussia, Pennsylvania--(Newsfile Corp. - October 19, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA therapeutic platform, including its lead clinical candidate PH-762 for the treatment of...

OS Therapies Announces Initial Closing of Warrant Exercise Inducement and Exchange Offer for Initial Gross Proceeds of Approximately $7.2 Million

Mon, 19 Oct 2026 08:30:00 -0400

Proceeds from the initial closing, together with accrued refundable U.K. R&D tax credits, expected to provide operating runway through major upcoming milestonesCompany expects to complete early market access regulatory approval submissions for Herlystic™ ("OST-HER2" or "daznelimgene lisbac") in the U.S., U.K., Europe and Australia in the fourth quarter of 2026Grasonville, Maryland--(Newsfile Corp. - October 19, 2026) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"),...

CBIH Announces Expanded Research Strategy at the Intersection of Endocannabinoid Science and Biological Medicine

Mon, 19 Oct 2026 07:00:00 -0400

Houston, Texas--(Newsfile Corp. - October 19, 2026) - Cannabis Bioscience International Holdings, Inc. (OTC Pink: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announced an expansion of its scientific research strategy focused on the intersection of endocannabinoid biology, precision medicine, and the development of intellectual property with potential biomedical applications."We are witnessing a new era in the history of medicine: an era in which human biology...